Method of treating cancers using β-lapachone or analogs or derivatives thereof
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/506
A61K-031/497
A61K-031/4965
출원번호
US-0726467
(2003-12-02)
등록번호
US-7361691
(2008-04-22)
발명자
/ 주소
Li,Chiang
Li,Youzhi
출원인 / 주소
Arqule, Inc.
대리인 / 주소
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
인용정보
피인용 횟수 :
0인용 특허 :
9
초록▼
Cancers and/or malignancies can be treated by administration of a cell cycle checkpoint activator, which is preferably β-lapachone, or a derivative or analog thereof, combined with an oncogenic kinase modulator, preferably imatinib. This combination of the cell cycle checkpoint activator with t
Cancers and/or malignancies can be treated by administration of a cell cycle checkpoint activator, which is preferably β-lapachone, or a derivative or analog thereof, combined with an oncogenic kinase modulator, preferably imatinib. This combination of the cell cycle checkpoint activator with the oncogenic kinase modulator results in an unexpectedly greater than additive (i.e., synergistic) apoptosis in cancer cells. The invention includes methods of treating cancers by administering the combination of the cell cycle checkpoint activator and the oncogenic kinase modulator, pharmaceutical compositions comprising the combination of drugs used in these methods, as well as pharmaceutical kits.
대표청구항▼
What is claimed is: 1. A method of treating multiple myeloma in a human, the method comprising administering to the subject a therapeutically effective amount of β-lapachone and imatinib, such that the multiple myeloma is treated. 2. The method of claim 1, wherein β-lapachone and imatin
What is claimed is: 1. A method of treating multiple myeloma in a human, the method comprising administering to the subject a therapeutically effective amount of β-lapachone and imatinib, such that the multiple myeloma is treated. 2. The method of claim 1, wherein β-lapachone and imatinib are administered intravenously, orally or intraperitoneally. 3. The method of claim 1, wherein β-lapachone and imatinib are administered orally. 4. The method of claim 1, wherein imatinib is administered orally. 5. The method of claim 1, wherein β-lapachone is administered intravenously. 6. The method of claim 1, wherein imatinib is administered simultaneously with, preceding administration of, or following administration of β-lapachone. 7. The method of claim 6, wherein imatinib is administered following administration of β-lapachone. 8. The method of claim 7, wherein imatinib is administered within 24 hours after β-lapachone is administered. 9. The method of claim 1, wherein the therapeutically effective amount of β-lapachone is contained in a first vial, and imatinib is contained in a second vial, the contents of the first and second vials being administered to the patient simultaneously or sequentially. 10. The method of claim 1, wherein imatinib is administered at a dosage of approximately 400, 600 or 800 mg/day. 11. The method of claim 1, wherein β-lapachone is administered at a dosage from about 100 to 500,000 μg per kilogram body weight of recipient per day. 12. The method of claim 1, wherein β-lapachone is administered at a dosage from about 1000 to 250,000 μg per kilogram body weight of recipient per day. 13. The method of claim 1, wherein β-lapachone is administered at a dosage from about 10,000 to 150,000 μg per kilogram body weight of recipient per day. 14. The method of claim 1, wherein β-lapachone is administered at a dosage from about 2 mg/m2 to 5000 mg/m2 per day. 15. The method of claim 1, wherein β-lapachone at a dosage from about 20 mg/m2 to 500 mg/m2 per day. 16. The method of claim 1, wherein β-lapachone is administered at a dosage from about 30 to 300 mg/m2 per day. 17. The method of claim 1, wherein β-lapachone further comprises a pharmaceutically acceptable carrier. 18. The method of claim 17, wherein the pharmaceutically acceptable carrier is a water solubilizing carrier molecule selected from the group consisting of Poloxamer, Povidone K17, Povidone K12, Tween 80, ethanol, Cremophor/ethanol, polyethylene glycol (PEG) 400, propylene glycol, Trappsol, alpha-cyclodextrin, beta-cyclodextrin, and gamma-cyclodextrin. 19. The method of claim 1, wherein the subject is human.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (9)
Rahman Aquilur (Gaithersburg MD) Rafaeloff Rafael (Tel-Aviv MD ILX) Husain Syed R. (Gaithersburg MD), Liposome encapsulated taxol and a method of using the same.
Frydman Benjamin J. ; Witiak Donald T. ; Sun Jerry Shunneng ; Geiser Andrew H., Ortho-quinone derivatives novel synthesis therefor and their use in the inhibition of neoplastic cell growth.
Frydman Benjamin J. ; Witiak ; deceased Donald T. ; Sun Jerry Shunneng ; Geiser Andrew H., Ortho-quinone derivatives, novel synthesis therefor, and their use in the inhibition of neoplastic cell growth.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.